Skip to content

TCA Cycle in the Dentate in Friedreich's Ataxia

Measurement of the TCA Cycle Rate in the Dentate Nucleus in Friedreich's Ataxia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03122925
Enrollment
20
Registered
2017-04-21
Start date
2017-08-29
Completion date
2023-01-11
Last updated
2023-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Friedreich Ataxia

Brief summary

OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a group of control subjects and subjects with Friedreich's Ataxia (FRDA). HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The investigators will infuse carbon-13 (13C) labeled glucose and measure the rate of 13C label incorporation from glucose to glutamate in the brain using in vivo magnetic resonance spectroscopy.

Detailed description

The investigators will measure the TCA cycle rate in the dentate nucleus in a group of FRDA patients and in a group of age-matched healthy controls using 13C MRS in vivo together with systemic i.v. infusion of 13C-labeled glucose. The investigators aim to obtain adequate data in 16 subjects grouped as follows: * n=4 pilot subjects (healthy subjects) for testing and optimization of the experimental setup. * n=6 healthy controls * n=6 FRDA patients In other to reach this goal, the investigators plan to recruit up to 20 subjects, in case some subjects withdraw before completion of the MR scan, or in case the measured data are not adequate (e.g. technical problem with the scanner).

Interventions

DEVICEMR

MR

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years of age or older * able to consent for themselves * considered healthy (controls) OR be diagnosed with FRDA.

Exclusion criteria

* All subjects: * Participants who cannot have an MRI, as determined by the CMRR safety screening form (e.g. metal implant) * Pregnancy * Clautrophobia * Diabetes * Clinically significant cardiac disease Control subjects: \- Neurological disease

Design outcomes

Primary

MeasureTime frameDescription
TCA cycle rate in the dentate nucleusBaselinevalue between 0 to 2 micromol/g/min

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026